| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
11,060,000 |
| Market
Cap: |
244.20(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.53 - $29 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 7.1 |
| Insider 6 Months : 7.1 |
| Insider 3/6 Months : 14.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. Co.'s clinical pipeline includes an inhaled IL-4Ra antagonist Anticalin protein to treat uncontrolled asthma and an immuno-oncology (IO) bispecific targeting HER2 and 4-1BB and, an IO bispecific targeting PD-L1 and 4-1BB. Co. has intellectual property rights directed to various aspects of its Anticalin technology platform, allowing for the development and improvement of both its platform and drug candidates. Co.'s development plans focus on two main areas, respiratory diseases and IO.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
4,990 |
4,990 |
14,991 |
14,991 |
| Total Buy Value |
$100,797 |
$100,797 |
$244,844 |
$244,844 |
| Total People Bought |
1 |
1 |
3 |
3 |
| Total Buy Transactions |
2 |
2 |
6 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jenkins George M |
Director |
– • – |
2025-04-09 |
4 |
B |
$20.27 |
$50,472 |
I/I |
2,490 |
13,516 |
2.1 |
1% |
|
| Jenkins George M |
Director |
– • – |
2025-04-09 |
4 |
B |
$20.13 |
$50,325 |
D/D |
2,500 |
183,171 |
2.39 |
1% |
|
| Jenkins George M |
Director |
– • – |
2024-12-18 |
4 |
B |
$12.93 |
$51,720 |
D/D |
4,000 |
180,671 |
2.39 |
104% |
|
| Kaupinen Wes |
President & CEOOfficer |
• • • |
2024-12-13 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
44,410 |
|
- |
|
| Lampert Mark N |
See Explanation of Responses |
– – – |
2024-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
438,929 |
38,961 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2024-12-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,879 |
|
81% |
|
| Heron Elaine J |
Director |
– • – |
2024-12-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
45,412 |
|
81% |
|
| Jenkins George M |
Director |
– • – |
2024-12-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
11,026 |
|
81% |
|
| Jenkins George M |
Director |
– • – |
2024-12-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
176,671 |
|
81% |
|
| Geraghty James A |
Director |
• • – |
2024-12-12 |
4 |
D |
$0.01 |
$0 |
D/D |
(1) |
0 |
|
- |
|
| Adar1 Partners, Lp |
10% Owner |
– – • |
2024-08-12 |
4 |
B |
$15.88 |
$47,647 |
I/I |
3,000 |
15,067 |
1.5 |
-26% |
|
| Adar1 Partners, Lp |
10% Owner |
– – • |
2024-08-09 |
4 |
B |
$14.89 |
$44,679 |
I/I |
3,000 |
127,331 |
1.5 |
-26% |
|
| Geraghty James A |
Director |
• • – |
2024-08-07 |
4 |
B |
$1.00 |
$1 |
D/D |
1 |
1 |
2.31 |
-17% |
|
| Kiritsy Christopher P |
|
– • – |
2023-05-25 |
4 |
B |
$0.85 |
$8,500 |
D/D |
10,000 |
20,000 |
0.01 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2023-05-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,333,557 |
|
- |
|
| Demuth Tim |
Chief Medical Officer |
• – – |
2022-05-13 |
4 |
B |
$1.71 |
$10,260 |
D/D |
6,000 |
6,000 |
2.74 |
- |
|
| Olwill Shane |
Chief Development Officer |
• – – |
2021-08-30 |
4 |
S |
$5.00 |
$196,380 |
D/D |
(38,400) |
4,638 |
|
- |
|
| Olwill Shane |
Chief Development Officer |
• – – |
2021-08-30 |
4 |
OE |
$1.52 |
$58,368 |
D/D |
38,400 |
43,038 |
|
- |
|
| Olwill Shane |
Chief Development Officer |
• – – |
2021-08-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,638 |
|
- |
|
| Aquilo Capital Management, Llc |
10% Owner |
– – • |
2020-07-21 |
4 |
S |
$2.95 |
$5,605,000 |
I/I |
(1,900,000) |
3,675,530 |
|
- |
|
| Aquilo Capital Management, Llc |
10% Owner |
– – • |
2020-03-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,575,530 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2019-09-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,982,268 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2019-09-06 |
4 |
S |
$4.50 |
$224,970 |
D/D |
(50,000) |
314,139 |
|
- |
|
| Bures Thomas |
Vice President, Finance |
• – – |
2019-09-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,109 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2019-01-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,000,000) |
141,346 |
|
- |
|
43 Records found
|
|
Page 1 of 2 |
|
|
1.46 (7.08%) 
